Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002

Journal of Infection

Volumn 49, Issue 2, 2004, Pages 109-114

  Morrissey, Ian ^a   Burnett, Ray ^b   Viljoen, Louise ^a   Robbins, Marion ^a  

^a GR Micro Ltd   (United Kingdom)

^b ALLERGAN PLC   (United States)

Author keywords

Conjunctivitis; Fluoroquinolones; Gatifloxacin; Keratitis

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; FUSIDIC ACID; GATIFLOXACIN; GENTAMICIN; METICILLIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EUROPE; EYE INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE FACILITY; HEALTH SURVEY; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EUROPE; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE;

EID: 3242793435     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.03.007     Document Type: Article

References (14)

1. Miller M.H. Mayers M. Treatment of eye infections Hooper D.C. Rubinstein E. Quinolone antimicrobial agents 3rd ed. 2003 291-309 ASM Press Washington
2. Jensen H.G. Felix C. The In Vitro Antibiotic Testing Group In vitro antibiotic susceptibilities of ocular isolates in North and South America Cornea 17 1998 79-87
3. Egger S.F. Ruckhofer J. Alzner E. et al. In vitro susceptibilities to topical antibiotics of bacteria isolates from the surface of clinically symptomatic eyes Ophthal Res 33 2001 117-120
4. Blondeau J.M. Gatifloxacin: a new fluoroquinolone Expert Opin Investig Drugs 9 2000 1877-1895
5. Saravolatz L.D. Leggett J. Gatifloxacin, gemifloxacin and moxifloxacin: the role of 3 newer fluoroquinolones Clin Infect Dis 37 2003 1210-1215
6. Allergan; data on file.
7. National Committee for Clinical Laboratory Standards (NCCLS) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2000 NCCLS Wayne, PA
8. National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial sensitivity testing 2003 NCCLS Wayne, PA
9. Diekma D.J. Pfaller M.A. Schmitz F.J. et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific Region for the SENTRY program, 1997-1999 Clin Infect Dis 32 Suppl 2 2001 S114-S132
10. Jacobs M.R. Felmingham D. Appelbaum P.C. et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229-246
11. Hoban D. Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections J Antimicrob Chemother 50 2002 49-59
12. Felmingham D. Reinert R.R. Hirakata Y. Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin J Antimicrob Chemother 50 2002 25-37
13. Sader H.S. Biedenbach D.J. Jones R.N. Global patterns of susceptibility for 21 commonly utilised antimicrobial agents tested against 48 400 Enterobacteriaceae isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001) Diagn Microbiol Infect Dis 47 2003 264-361
14. Jones R.N. Sader S. Beach M.L. Contemporary spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli Enterobacteriaceae isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001) Int J Antimicrob Agents 22 2003 551-556